Ciliatech SAS received a U.S. FDA investigational device exemption (IDE) for its Intercil Uveal Spacer implant, enabling a feasibility study for the company’s glaucoma approach. The implant is positioned as a treatment to address glaucoma, with the IDE serving as a regulatory gateway to evaluate safety and feasibility before broader development. The FDA’s IDE clearance marks a concrete step from concept into controlled clinical evaluation. For medtech manufacturers, the decision shows how device teams can progress when clinical pathways are clearly defined, particularly in ophthalmology where surgical and implant innovations compete on outcomes and usability. The next milestones will be driven by study execution, patient selection, and endpoint selection aligned to the device’s intended mechanism of action.